All 2025 News
-
First General Session features potentially practice-changing findings, including data from lidERA and HER2CLIMB-05 trials
Erika Hamilton, MD; Joseph A. Sparano, MD; Komal Jhaveri, MD; and Aditya Bardia, MD, MPH, were among the experts reporting results Wednesday during the General Session at the San Antonio Breast Cancer Symposium.
-
McGuire Lecture Awardee shares lessons on change from pioneering work on sentinel lymph node biopsy
2025 William L. McGuire Memorial Lecture Award recipient Armando E. Giuliano, MD, reflected on successes and setbacks related to his career-defining studies.
-
SABCS Schedule Spotlight for Thursday, December 11
Plan your Thursday schedule and don’t miss notable items on the program, including the second General Session, the FDA session on recent approvals for hormone receptor-positive metastatic breast cancer, and more.
-
Controversies session to spotlight complex multidisciplinary decisions in axillary management
Tari A. King, MD, will moderate a Thursday afternoon session on a shift toward de-escalating axillary surgery and regional nodal radiation after neoadjuvant chemotherapy in clinically node positive patients.
-
AACR to honor pioneering breast cancer researchers during SABCS 2025
The American Association for Cancer Research (AACR) will recognize two researchers for significant contributions to breast cancer research. Ben Ho Park, MD, PhD, will deliver a lecture late Thursday afternoon, and Sara M. Tolaney, MD, MPH, will speak early Friday afternoon.
-
SABCS Snippets: Results from the Phase III HER2CLIMB-05 Trial
Julie Nangia, MD, talks with Erika Hamilton, MD, about the results of the HER2CLIMB-05 study, a Phase III trial that demonstrated that adding tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy.
-
SABCS Snippets: Results from the Phase III ASCENT-07 Trial
Saba Shaikh, MD, talks with Komal Jhaveri, MD, about the results of the ASCENT-07 study, which demonstrated that patients with HR-positive, HER2-negative advanced breast cancers had similar progression-free survival whether they were treated with sacituzumab govitecan-hziy or standard-of-care chemotherapy as the first treatment after endocrine therapy.
-
SABCS Snippets: Lobular Breast Cancer
Rahul Gosain, MD, of the Oncology Brothers, talks with Marleen Kok, MD, PhD, about how lobular carcinoma — which comprises 10-15% of all invasive breast cancers — differs from ductal carcinoma.
-
SABCS Snippets: Obesity and Breast Cancer Risk
Rohit Gosain, MD, of the Oncology Brothers, talks with Kristy Brown, PhD, about the biological link between obesity and risk of breast cancer.
-
SABCS Snippets: Beyond CDK4/6 Inhibitors
SABCS Program Director Kate Lathrop, MD, talks with Shom Goel, MBBS, PhD, about CDK4/6 inhibitors and emerging options to advance treatment for HR-positive, HER-negative metastatic breast cancer.